The Brokerages Set Abiomed Inc. (ABMD) PT at $137.50

The Brokerages Set Abiomed Inc. (ABMD) PT at $137.50

Abiomed Inc. (NASDAQ:ABMD) has been assigned an average recommendation of “Buy” from the eight research firms that are presently covering the company. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $137.50.

ABMD has been the subject of a number of recent research reports. Leerink Swann reiterated an “outperform” rating and set a $125.00 price target on shares of Abiomed in a report on Wednesday, September 28th. TheStreet downgraded shares of Abiomed from a “buy” rating to a “hold” rating in a report on Thursday, October 27th. Zacks Investment Research upgraded shares of Abiomed from a “hold” rating to a “strong-buy” rating and set a $146.00 price target for the company in a report on Wednesday, October 5th. Guggenheim initiated coverage on shares of Abiomed in a report on Tuesday, December 6th. They set a “buy” rating and a $150.00 price target for the company. Finally, BTIG Research reiterated a “buy” rating and set a $170.00 price target on shares of Abiomed in a report on Sunday, January 8th.

In other Abiomed news, Director Dorothy E. Puhy sold 8,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 13th. The shares were sold at an average price of $120.00, for a total transaction of $960,000.00. Following the completion of the sale, the director now directly owns 32,749 shares in the company, valued at $3,929,880. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 10.00% of the stock is currently owned by corporate insiders.

A number of large investors have recently added to or reduced their stakes in the company. Cypress Capital Management LLC WY acquired a new stake in Abiomed during the second quarter valued at about $106,000. Creative Planning increased its stake in Abiomed by 53.3% in the third quarter. Creative Planning now owns 984 shares of the company’s stock valued at $127,000 after buying an additional 342 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Abiomed by 13.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,314 shares of the company’s stock valued at $169,000 after buying an additional 155 shares in the last quarter. Private Bank & Trust Co. acquired a new stake in Abiomed during the third quarter valued at about $203,000. Finally, Advisor Group Inc. acquired a new stake in Abiomed during the second quarter valued at about $204,000. Institutional investors own 91.40% of the company’s stock.

Shares of Abiomed (NASDAQ:ABMD) opened at 113.27 on Thursday. The firm has a market capitalization of $4.89 billion, a price-to-earnings ratio of 116.77 and a beta of 0.49. The firm’s 50-day moving average is $114.26 and its 200-day moving average is $117.58. Abiomed has a 12-month low of $67.81 and a 12-month high of $132.95.

Abiomed (NASDAQ:ABMD) last issued its quarterly earnings results on Thursday, October 27th. The company reported $0.20 EPS for the quarter, missing analysts’ consensus estimates of $0.24 by $0.04. The firm had revenue of $103 million for the quarter, compared to analysts’ expectations of $103.16 million. Abiomed had a return on equity of 11.63% and a net margin of 11.24%. The business’s quarterly revenue was up 35.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.17 earnings per share. Equities research analysts forecast that Abiomed will post $1.13 EPS for the current fiscal year.

About Abiomed

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Related posts

Leave a Comment